Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of RO7616789 in advanced small cell lung cancer and other neuroendocrine carcinomas
jRCT2031220511Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of RG6538 in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability, Preliminary antitumor activity and 3 more. Started Jan 2023; status: completed.
02
Drugs
RG6538
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on jRCT2031220511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220511.